NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

CompletedEARLY_Phase 1

Sponsor: Stanford University

Conditions: Cardiovascular Diseases, Atherosclerosis, Type 2 Diabetes, Insulin Resistance

Interventions: Ertugliflozin

Countries: United States

The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.

Eligibility overview

Sex: ALL

Age: 18 Years to 80 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass surgery or vascular surgery
* history of Diabetes Mellitus Type 2 currently diet controlled, or on metformin or dpp4 inhibitors

Exclusion Criteria:

* allergy or intolerance to interventional medication
* currently taking insulin, glp-1 inhibitors, or sulfonylureas

Locations (1)

Stanford, California, United States